

17 October 2016

ASX ANNOUNCEMENT

BIOXYNE COMMENCES RECRUITMENT FOR CLINICAL TRIAL OF ITS PROPRIETARY PROBIOTIC

Bioxyne Limited (ASX:BXN) today announced that advertising has commenced to recruit sixty Sydney-based healthy adult volunteers into a randomized, double-blind, placebo controlled clinical trial examining the effects of Bioxyne's patented human-isolated probiotic strain, PCC[®], on gastrointestinal health and general well-being.

PCC[®] (*Lactobacillus fermentum* VRI-003) has been sold as a dietary supplement in capsule and powder form for over 10 years worldwide with no reported adverse effects. Several clinical studies have demonstrated its ability to boost immune health in people.

The study's primary outcome is to determine the effect of daily consumption of PCC[®] in capsules for six months on the composition of the gut bacteria. The types of bacteria in the gastrointestinal tract are known to have significant effects on human health, and PCC[®]'s ability to positively influence these bacteria will be examined in this trial. The secondary outcomes include effects on bowel function, weight loss and general well-being through a self - assessment questionnaire.

The effect of PCC[®] on the composition of the gut microbiome will be quantitatively analysed using kits from Melbourne-based smartDNA Pty Limited. This technology uses nucleic acid analysis to identify the thousands of species present in the gastrointestinal tract, and each volunteer's microbiome will be analysed before, during and at the end of the 6 month trial.

"We believe that this is the first time that a probiotic has been tested for its long term effect on the gut microbiome in healthy humans," Dr Peter French, Scientific Director and the designer of the trial explained. "PCC[®] has been demonstrated in previous trials to have beneficial effects on boosting the immune system of elite male athletes and infants, as well as boosting the immune response to the flu vaccine. Scientific studies have previously indicated that PCC[®] exerts its potent effect on the immune system via the gastrointestinal tract. This study is designed to confirm that mechanism."

Data from the study will be used to promote the gastrointestinal benefits of PCC® generally and of the company's soon to be launched Australian probiotic product, Progastrim®, in particular.

"Bioxyne is committed to demonstrating the clinical efficacy of PCC® to assist in the marketing of its current products as well as new products in new markets," Bioxyne's Chairman Mr Tony Ho commented. "We are pleased to commence an extensive clinical trial program aimed at supporting sales and marketing efforts of PCC®-containing products worldwide."

Dr. Peter French, Scientific Director, Bioxyne Limited

+61 412 457 595

Guy Robertson, Chief Operating Officer, Bioxyne Limited

+61 2 9078 8180 or +61 407 983 270

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian life sciences, health and medical technologies company (incorporated in 2000) with a focus on immune health and immunotherapeutic products.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne's focus is currently on the company's probiotic business and proprietary product *Lactobacillus fermentum* PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.